427 related articles for article (PubMed ID: 18562427)
1. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety.
Bailey JE; Papadopoulos A; Seddon K; Nutt DJ
J Psychopharmacol; 2009 Mar; 23(2):117-22. PubMed ID: 18562427
[TBL] [Abstract][Full Text] [Related]
2. GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety?
Bailey JE; Nutt DJ
Pharmacol Biochem Behav; 2008 Jul; 90(1):51-7. PubMed ID: 18485466
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.
de Haas SL; de Visser SJ; van der Post JP; Schoemaker RC; van Dyck K; Murphy MG; de Smet M; Vessey LK; Ramakrishnan R; Xue L; Cohen AF; van Gerven JM
J Psychopharmacol; 2008 Jan; 22(1):24-32. PubMed ID: 18187530
[TBL] [Abstract][Full Text] [Related]
4. The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures.
Papadopoulos A; Rich A; Nutt DJ; Bailey JE
J Psychopharmacol; 2010 May; 24(5):649-56. PubMed ID: 18832434
[TBL] [Abstract][Full Text] [Related]
5. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group.
Lydiard RB; Ballenger JC; Rickels K
J Clin Psychiatry; 1997; 58 Suppl 11():11-8. PubMed ID: 9363043
[TBL] [Abstract][Full Text] [Related]
6. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam.
Klein E
J Clin Psychiatry; 2002; 63 Suppl 14():27-33. PubMed ID: 12562116
[TBL] [Abstract][Full Text] [Related]
7. Subjective experience and attitudes towards participation in clinical trials among patients with anxiety disorders.
Klein E; Malel D; Zilberman I; Lenox RH
Isr J Psychiatry Relat Sci; 1997; 34(4):265-9. PubMed ID: 9409083
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety.
Bailey JE; Papadopoulos A; Diaper A; Phillips S; Schmidt M; van der Ark P; Dourish CT; Dawson GR; Nutt DJ
J Psychopharmacol; 2011 Sep; 25(9):1199-206. PubMed ID: 21555331
[TBL] [Abstract][Full Text] [Related]
9. The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans.
Lu K; Gray MA; Oliver C; Liley DT; Harrison BJ; Bartholomeusz CF; Phan KL; Nathan PJ
Hum Psychopharmacol; 2004 Oct; 19(7):457-65. PubMed ID: 15378679
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic.
Diaper A; Osman-Hicks V; Rich AS; Craig K; Dourish CT; Dawson GR; Nutt DJ; Bailey JE
J Psychopharmacol; 2013 Feb; 27(2):135-45. PubMed ID: 22516666
[TBL] [Abstract][Full Text] [Related]
11. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
Pols H; Verburg K; Hauzer R; Meijer J; Griez E
Biol Psychiatry; 1996 Nov; 40(9):913-7. PubMed ID: 8896779
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.
de Haas SL; de Visser SJ; van der Post JP; de Smet M; Schoemaker RC; Rijnbeek B; Cohen AF; Vega JM; Agrawal NG; Goel TV; Simpson RC; Pearson LK; Li S; Hesney M; Murphy MG; van Gerven JM
J Psychopharmacol; 2007 Jun; 21(4):374-83. PubMed ID: 17092968
[TBL] [Abstract][Full Text] [Related]
13. Oxidative metabolism of limbic structures after acute administration of diazepam, alprazolam and zolpidem.
González-Pardo H; Conejo NM; Arias JL
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1020-6. PubMed ID: 16647177
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature.
Jonas JM; Cohon MS
J Clin Psychiatry; 1993 Oct; 54 Suppl():25-45; discussion 46-8. PubMed ID: 8262888
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study.
Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Barbanoj MJ
Psychopharmacology (Berl); 2001 Oct; 157(4):358-67. PubMed ID: 11605094
[TBL] [Abstract][Full Text] [Related]
16. High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience.
Tesar GE
J Clin Psychiatry; 1990 May; 51 Suppl():4-10; discussion 50-3. PubMed ID: 1970816
[TBL] [Abstract][Full Text] [Related]
17. Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions.
Bradwejn J
Can J Psychiatry; 1993 Nov; 38 Suppl 4():S109-13. PubMed ID: 7905780
[TBL] [Abstract][Full Text] [Related]
18. Generalized anxiety disorder versus panic disorder: participation in controlled efficacy trials.
Mavissakalian MR; Zamar N
Compr Psychiatry; 2000; 41(4):253-8. PubMed ID: 10929792
[TBL] [Abstract][Full Text] [Related]
19. [Clinical comparison between alprazolam and lorazepam. A polycentric study in double blind].
Botte L; Bienfait J; Dethier J; Even P; Evrard JL; Fraipont J; Goffin L; Willemse P
Acta Psychiatr Belg; 1981; 81(6):595-608. PubMed ID: 6125089
[TBL] [Abstract][Full Text] [Related]
20. Alprazolam and diazepam in the treatment of generalized anxiety.
Elie R; Lamontagne Y
J Clin Psychopharmacol; 1984 Jun; 4(3):125-9. PubMed ID: 6145726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
